Compare Danaher Corporation (DHR) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Under Armour Inc Class A — how do they compare? Danaher Corporation trades at $207.24 (market cap $145.83B), while Under Armour Inc Class A trades at $5.13 (market cap $2.26B). The key difference: Danaher Corporation is far larger — about 64.5× Under Armour Inc Class A's market cap, and Danaher Corporation pays a 0.77% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| DHR | UA | |
|---|---|---|
Market Cap | $145.83B | $2.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $7.88 |
52-Week Low | $161.91 | $3.96 |
Enterprise Value | $168.04B | $3.24B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Under Armour (UA) trades at $5.14, down 9.43% amid bearish technical signals and negative profitability metrics. The company reported Q1 2026 revenue of $1.1 billion, missing expectations, and lowered its fiscal 2027 revenue outlook due to soft consumer demand in North America and Asia-Pacific. Despite beating EPS estimates in two of the last three quarters, negative net income margin of -9.99% and declining revenue trends highlight ongoing challenges.
The stock faces significant headwinds from deteriorating fundamentals and negative cash flow, though analyst consensus remains cautiously optimistic with 38.8% buy ratings. Key risks include continued revenue declines, competitive pressure, and execution challenges in the turnaround strategy. The current valuation at 0.45 P/S offers potential value if management can stabilize operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
